Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) FCF Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed FCF Margin for 13 consecutive years, with 32.56% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 166.0% to 32.56% in Q3 2025 year-over-year; TTM through Sep 2025 was 303.15%, a 32072.0% increase, with the full-year FY2024 number at 18.43%, down 127311.0% from a year prior.
  • FCF Margin was 32.56% for Q3 2025 at Theravance Biopharma, down from 794.33% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 794.33% in Q2 2025 to a low of 1077.36% in Q1 2022.
  • A 5-year average of 47.6% and a median of 31.22% in 2024 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 323457bps in 2021, then plummeted -57493bps in 2022.
  • Theravance Biopharma's FCF Margin stood at 502.43% in 2021, then skyrocketed by 174bps to 373.04% in 2022, then crashed by -131bps to 116.72% in 2023, then surged by 95bps to 5.82% in 2024, then crashed by -459bps to 32.56% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's FCF Margin are 32.56% (Q3 2025), 794.33% (Q2 2025), and 279.69% (Q1 2025).